# Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment

> **NCT06666114** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 232 (actual)

## Conditions studied

- Psoriasis (PsO)
- Psoriatic Arthritis (PsA)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06666114
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-03
- **Primary completion:** 2023-10-10
- **Final completion:** 2023-10-10
- **Target enrollment:** 232 (ACTUAL)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06666114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06666114, "Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06666114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*